Ovarian Cancer (update of OV28)
Project summary
Ovarian cancer accounts for 6% of all female cancer deaths and is the cause of more deaths in women than all other gynaecological malignancies combined. Measuring QoL to evaluate the treatment options of different types of cancer are crucial. Since the development of EORTC QLQ OV28 in 1997, more treatment options for ovarian cancer have become available and other side-effects have been reported. Therefore, an updated questionnaire will be developed.
Achievements
Literature-review was performed from
which studies using the existing
questionnaire can be identified as well as
new questionnaires with issues that are
not included in the existing ones.
Activation of collaborating sites.
Investigator package has been sent out and the collaborators handed in ethics or and performed interviews with patients and HCPs.
Current status:
Waiting for feedback of some collaborators for missing data. Currently, the data of the Phase II is analysed.
Future plans
We plan to present the final results of the data for phase I and Phase II at the QOL meeting in Copenhagen. The report for phase I and II will be written by end of October 2025.
For patients
When evaluating the impact of an illness such as cancer, one of the most important areas to consider is the effect on quality of life. In this study, a literature review and interviews with patients and health care professionals will be conducted to help us understand the impact of ovarian cancer on the quality of life of patients. Due to the rising number of new treatments, the question is if the existing questionnaire to assess the quality of life in patients diagnosed with ovarian cancer should be updated.